<DOC>
	<DOCNO>NCT00995904</DOCNO>
	<brief_summary>This Phase 2 study investigate tolerability unit dose budesonide ( MAP0020 ) three dos pediatric volunteer diagnosis history mild-to-moderate stable asthma evaluate pharmacokinetic profile budesonide result inhalation aerosol delivery .</brief_summary>
	<brief_title>Tolerability PK Submicron Budesonide Children 4 11 Years Old With Mild-To-Moderate Stable Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Key 1 . Male female child document diagnosis mildtomoderate persistent asthma ( accord 2007 NIH [ EPR ] criterion ) least 1 year prior screen medically stable minimum 6 month prior screen . 2 . Children 4 11 year old ( one day prior 12th birthday randomization ) . 3 . Body weight &gt; =45 lb , body mass index ( BMI ) &lt; =30 kg/m2 4 . ICS user take ICS &gt; =3 month stable dose &gt; = 1 month Visit 1.ICS user stable enough able withhold therapeutic ICS 24 hour prior study drug administration , 5 . Subjects already stable immunotherapy ( ie , allergy shot ) anticipate change study . Key 1 . Females childbearing potential/menarche . 2 . Diagnosis significant chronic illness abnormality . 3 . Use corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>asthmatic child</keyword>
</DOC>